Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KEZAR LIFE SCIENCES, INC.

(KZR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Mixed Pre-Bell Tuesday

11/16/2021 | 09:19am EST


ę MT Newswires 2021
All news about KEZAR LIFE SCIENCES, INC.
01/07KEZAR LIFE SCIENCES, INC. : Results of Operations and Financial Condition, Change in Direc..
AQ
2021KEZAR LIFE SCIENCES, INC. : Termination of a Material Definitive Agreement, Results of Ope..
AQ
2021KEZAR LIFE SCIENCES, INC.(NASDAQGS : KZR) added to S&P Biotechnology Select Industry Index
CI
2021KEZAR LIFE SCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Kezar Appoints Courtney Wallace to its Board of Directors
BU
2021Kezar Life Sciences, Inc. Announce Directorate Changes
CI
2021Wells Fargo Starts Kezar Life Sciences at Overweight With $19 Price Target
MT
2021Health Care Stocks Ease Slightly At Tuesday Close
MT
2021Health Care Stocks Helping Boost Tuesday Markets
MT
2021HC Wainwright Adjusts Price Target on Kezar Life Sciences to $20 from $12, Keeps Buy Ra..
MT
More news
Analyst Recommendations on KEZAR LIFE SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -56,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -11,4x
Yield 2021 -
Capitalization 605 M 605 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 47
Free-Float 71,2%
Chart KEZAR LIFE SCIENCES, INC.
Duration : Period :
Kezar Life Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KEZAR LIFE SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 12,32 $
Average target price 20,67 $
Spread / Average Target 67,7%
EPS Revisions
Managers and Directors
John Fowler Director
Christopher J. Kirk Director
Marc L. Belsky Chief Financial Officer
Jean-Pierre Sommadossi Chairman
Noreen Roth Henig Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
KEZAR LIFE SCIENCES, INC.-26.32%605
GILEAD SCIENCES, INC.-6.61%85 060
REGENERON PHARMACEUTICALS-2.71%64 237
VERTEX PHARMACEUTICALS4.10%58 125
WUXI APPTEC CO., LTD.-6.39%51 206
BIONTECH SE-39.28%37 805